My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Favipiravir (T-705)
    Favipiravir (T-705)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1430
    CAS #: 259793-96-9 Purity ≥98%

    Description: Favipiravir (formerly T-705; T705; T 705; Avigan), an approved antiviral drug used to treat influenza in Japan,  is a selective RNA-dependent RNA polymerase inhibitor. It has been used to treat influenza virus infections in Japan and is also being investigated for treating other viral infections such as SARS-CoV-2.  

    References: Antimicrob Agents Chemother. 2002 Apr;46(4):977-81; Antiviral Res. 2015 Nov;123:70-7. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)157.1 
    FormulaC5H4FN3O2 
    CAS No.259793-96-9 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 31 mg/mL (197.3 mM) 
    Water: 5 mg/mL (31.8 mM)
    Ethanol: 22 mg/mL (140.0 mM) 
    SMILES O=C(C1=NC(F)=CN=C1O)N
    Synonyms T705; Avigan; T-705; T 705; 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis.


    Kinase Assay: Favipiravir (also known as T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, it is used to treat influenza virus infections. Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses.


    Cell Assay: The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).

    In VivoIn influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. 
    Animal modelMice infected with influenza virus A/PR/8/34 
    Formulation & DosageDissolved in 0.5% methylcellulose; 200 mg/kg/day; oral administration
    ReferencesAntimicrob Agents Chemother. 2002 Apr;46(4):977-81; Antiviral Res. 2015 Nov;123:70-7.  


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Favipiravir (T-705)

    Effect of oral administration of T-705 on prevention of death in influenza virus-infected mice. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81.
     

    Favipiravir (T-705)

    Effect of oral administration of T-705 on lung virus yield in influenza virus-infected mice. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?